Ambrx, Inc, (San Diego, USA) is based on a fundamental advance in protein biosynthesis that enables the company to genetically engineer proteins with new amino acid building blocks beyond the common 20, enabling the biosynthesis of proteins with new physical, chemical and pharmacological properties. By combining the versatility of medicinal chemistry with modern biotechnology, Ambrx is transforming the field of protein-based medicines.